PGM2L1 expression associates with survival in triple negative breast cancer.
We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of phosphoglucomutase 2-like 1, encoded by PGM2L1 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, PGM2L1 expression was correlated with overall survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. PGM2L1 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.